MGNX(MacroGenics, Inc.) · 财务报表

MGNX(MacroGenics, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$77.45M$151.94M$58.75M$149.96M$149.50M
毛利润$74.80M$148.59M$58.13M$149.12M$149.50M
营业利润−$202.79M−$121.42M−$168.24M−$110.58M−$72.84M
净利润−$202.12M−$119.76M−$9.06M−$66.97M−$74.62M
经营现金流−$143.83M−$86.96M−$78.20M−$68.37M−$81.04M
自由现金流−$150.03M−$90.58M−$79.97M−$72.08M−$82.95M
摊薄每股收益$-3.37$-1.95$-0.15$-1.07$-1.18

MacroGenics, Inc. MGNX